Shares of BioLineRX (BLRX) soar 31.1% in premarket trading after the firm announces that it...

|By:, SA News Editor

Shares of BioLineRX (BLRX) soar 31.1% in premarket trading after the firm announces that it signed an exclusive agreement with French-based Genoscience to develop and commercialize its Hepatitis C treatment.